There is an urgent need for more targeted treatment options for patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC), although first-line treatment has shown potential in a clinical study.
A study pitted Spravato against quetiapine extended-release, with the results showing that J&J’s product was more effective in patients with treatment-resistant major depressive disorder.
The sponsorship from Janssen Pharmaceutical Companies will be used by the cancer support network to boost diversity in Phase I and Phase 2 clinical trials.
Miruna Sasu has been named president and CEO of the company, which uses RWD and analytics in advancing oncology drug development and clinical trial diversity.
The pharmaceutical company's clinical study is intended to examine critical gaps in care for people of color living with moderate to severe plaque psoriasis.
Johnson & Johnson has announced its intent to separate its Consumer Health business into a new publicly traded company: allowing J&J to put a sharpened focus on pharmaceuticals and medical devices.
Johnson & Johnson has announced results from the primary analysis of its Imbokodo Phase 2b HIV vaccine clinical trial, with data showing the investigational HIV vaccine candidate did not provide sufficient protection against HIV infection. A Phase...
The World Health Organization’s Solidarity PLUS trial will kick off in 52 countries, trialing three drugs to treat patients hospitalized with COVID-19.
The pharmaceutical firm reports a counterfeit version of its Symtuza HIV treatment has been found and pulled from shelves at three American pharmacies.
Johnson & Johnson reaches $20m settlement with two US counties on lawsuits regarding the opioid crisis, exits the upcoming federal trial involving several drug manufacturers.
Mallinckrodt announces a settlement agreement on a lawsuit included in the first federal trial over the opioid crisis, shortly after reaching a deal on a previous investigation.
J&J is ordered to pay $572m to the state of Oklahoma, after a court judgement found against the pharmaceutical company for its role in the opioid crisis.
Panelist during the opening session of the DIA Annual Meeting last week stressed the need to work collaboratively, bringing patients into the fold as co-creators of clinical trials to ‘create a whole new landscape for research.’
In the era of big data, the industry is working to address the ethical concerns of integrating patient information into the health care landscape – though a key challenge will be reaching a consensus on what constitutes reliable evidence.
Janssen has confirmed plans to close a supply chain facility in HyangNam, while Bayer is transferring manufacturing operations from Ansung, South Korea, to Berlin, Germany.
Johnson & Johnson’s McNeil unit has initiated another recall, this time involving 4m packs of Children’s Benadryl allergy tablets and around 800,000 bottles of junior-strength Motrin caplets.
Dutch biopharmaceutical company Crucell expects its operating loss for 2010 to be in the €20-25 million range, citing costs associated with microbial contamination at its Shingal facility in Korea as a key factor.
Pfizer has widen its recall of the cholesterol-fighting drug, Lipitor, after two more complaints of a musty odour emanating from the product’s bottles.
McNeil Consumer Healthcare has recalled all lots of its Tylenol Arthritis Pain caplet 100 count bottles in the US due to reports of nausea and stomach pain.
The latest ethical reputations of the world's largest
pharmaceutical companies have been revealed, with GlaxoSmithKline
(GSK) emerging as big pharma's Mother Theresa, according to a
recently-released compilation by Geneva-based...
The US Food and Drug Administration (FDA) has approved Janssen's
new drug Invega (paliperidone); the first new prescription drug for
the treatment of schizophrenia since 2003.
Researchers have uncovered a novel treatment that could prove to be
effective against tuberculosis (TB), a disease that has made a
comeback due to the emergence of resistant strains of the offending
bacterium and the spread of AIDS.
The Irish government is joining Johnson & Johnson subsidiary
Centocor in a €650 million investment in a new manufacturing
facility, it said this week. The move comes as some have questioned
the country's capacity to remain...
A US congressional committee has asked five drug makers for advice
on the measures they are taking to combat the counterfeiting and
diversion of prescription drugs.
3-Dimensional Pharmaceuticals (3DP) said this week that the
research term under its thrombin collaboration with two of the
Johnson & Johnson family of companies, Centocor and Johnson
& Johnson Pharmaceutical Research and Development,...
